MSKCC/Motzer Score Metastatic RCC
The MSKCC/Motzer Score for metastatic RCC stratifies patients into favorable, intermediate, or poor risk based on five pretreatment clinical factors to predict overall survival 1 [Level I evidence].
Indications for Use
Used in previously untreated metastatic RCC to stratify prognosis and guide trial enrollment or initial systemic‑therapy expectations. It assigns favorable (0 factors), intermediate (1–2), or poor risk (≥3) based on KPS <80%, low hemoglobin, high LDH, hypercalcemia, and time from diagnosis to therapy <1 year (validated in 670‑patient cohort showing OS 20, 10, and 4 months respectively 1 [Level I evidence]).
Insights & Cautions
Assign risk using hemoglobin < LLN, corrected calcium > ULN, Karnofsky <80%, LDH >1.5× ULN, time from diagnosis to treatment <1 year, and note its limitations. These factors predict markedly different OS (favorable ~20–28 months vs poor ~4–8 months) in validation cohorts 1 [Level II evidence].
Cautions: derived in cytokine-era; underperforms vs IMDC in targeted/IO therapy 2 [Level I evidence]. Not validated for non–clear cell histology.